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Abstract
Objective: The limited number of available grafts is one of the major obstacles of lung transplantation. Size-reduced lung transplantation
allows the use of oversized grafts for small recipients. Optimal lung size matching is vital to achieve best functional outcome and avoid potential
problems when using oversized grafts. We hypothesise that donor-predicted postoperative forced expiratory volume in 1 s (ppoFEV1) correlates
with the recipient best FEV1 after size-reduced lung transplant, being useful for the estimation of function outcome. Methods: All patients
undergoing size-reduced or standard bilateral lung transplantation were included (1992—2007). Donor ppoFEV1 was calculated and corrected
with respect to size reduction and correlated with recipient measured best FEV1 post-transplant. In addition, pre- and postoperative clinical data
including surgical complications and outcome of all size-reduced lung transplant recipients were compared with standard lung transplant
recipients. Results: A total of 61 size-reduced lung transplant recipients (lobar transplants, n = 20; anatomic or non-anatomic resection, n = 41)
were included and compared to 145 standard transplants. The mean donor—recipient height difference was statistically significant between the
two groups ( p = 0.0001). The mean donor ppoFEV1 was comparable with recipient best FEV1 (2.7  0.6 vs 2.6  0.7 l). There was a statistically
significant correlation between donor ppoFEV1 and recipient best FEV1 ( p = 0.01, r = 0.688). The 30-daymortality rate and 3-month, 1- and 5-year
survival rates were comparable between the two groups. Conclusions: In size-reduced lung transplantation, postoperative recipient best FEV1
could be predicted from donor-calculated and corrected FEV1 with respect to its size reduction. Compared to standard lung transplantation,
equivalent morbidity, mortality and functional results could be obtained after size-reduced lung transplantation.
# 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Lung transplantation is an established therapy for end-
stage lung disease. According to the recent International
Society for Heart and Lung Transplantation (ISHLT) report,
more than 20 000 adults underwent lung transplantation
between January 1995 and June 2007 [1]. The overall
outcome is improving, with survival rates being 78% at 1 year
and 51% at 5 years after lung transplant, according to the
report [1]. Others and we have reported even superior
outcome results for selected patients, particularly in cystic
fibrosis (CF) [2,3]. Improvements in outcome are due to
better donor organ preservation and operative techniques,
enhanced immunosuppressant drug management and pre-* Corresponding author. Address: Division of Thoracic Surgery, University
Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland.
Tel.: +41 44 255 8802; fax: +41 44 255 8805.
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doi:10.1016/j.ejcts.2010.05.019vention of infection. However, there is an ongoing paucity of
suitable donor organs as the availability of cadaveric donor
lungs has failed to increase with the rise in numbers of
transplant candidates. For transplant recipients requiring
bilateral lung transplantation, donor-to-recipient supply and
demand mismatch is even further increased [4]. Due to the
increasing scarcity of donors, in particular for smaller
recipients, advanced operative strategies have been devel-
oped [5—10]. Size-reduced lung transplantation is increas-
ingly performed, often in urgent cases. Peripheral segmental
resection is the most common method for downsizing,
whereas lobar and split-lung transplants are the other
options performed [5—10]. Whenever size-reduced lung
transplants are undertaken, appropriate size matching of
donor organs and the recipient is vital. Oversized lung grafts
can potentially lead to atelectasis and impaired airway
clearance due to bronchial anatomy distortion. Undersized
grafts cause lung hyperexpansion and might limit exercise
tolerance due to haemodynamic compromise. In mostSurgery. Published by Elsevier B.V. All rights reserved.
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capacity (TLC) for size matching; however, its predictive
value for post-transplant lung function is uncertain. A recent
study including 27 size-reduced lung transplant recipients
concluded that postoperative TLC can be predicted by donor
TLC, corrected by the number of transplanted lung segments
[5]. We hypothesise that the donor-predicted postoperative
forced expiratory volume in 1 s (ppoFEV1) correlates with the
recipient best FEV1 after size-reduced lung transplantation,
being a useful tool for the estimation of functional outcome
post-transplant.
2. Material and methods
Patients undergoing primary bilateral lung transplantation
at the University Hospital Zurich, Switzerland, between
January 1992 and December 2007 were included in the study
and subdivided into two groups: size-reduced lung trans-
plants and standard lung transplants. Patients after single-
lung, heart—lung and lung re-transplantation were excluded
from the study. All patients’ demographic data were
collected retrospectively.
At our centre, we follow the recently published ISHLT
guidelines regarding referral and selection of lung transplant
candidates [11]. Organ preservation was performed with
Euro-Collins solution (until 2000), thereafter with PerfadexW
(Vitrolife, Gothenburg, Sweden). Before antegrade flush,
500 mg prostaglandin E1 (Prostin VR, Upjohn, Puurs, Belgium)
was injected into the pulmonary artery in all cases.
Harvesting of the donor lungs were undertaken en bloc after
perfusion. Since 2000, we also use retrograde flush with
PerfadexW at the time of the back-table preparation. The
decision to perform size-reduced lung transplantation was
made in the operating theatre during implantation. Periph-
eral segmental wedge resections were undertaken with a
commercially available stapler device. For lobar transplants,
lobectomy was done on the back table. For bilateral
sequential lung transplants, bilateral trans-sternal anterior
thoracotomy (clamshell incision) or two separate anterolat-
eral thoracotomies (since 2000) were performed. First, the
bronchial anastomosis was done followed by venous (atrial
cuff) and pulmonary artery anastomosis. The recipient’s main
bronchus was divided one ring proximal to the upper lobe
bronchus branch. Bronchial arteries were ligated off the peri-
bronchial tissue without electrocoagulation. All dissection on
the bronchus was performed using ‘minimal’ or ‘no touch’
technique to keep the peri-bronchial tissue intact. The donor
bronchus was cut back as close as possible to the origin of the
upper lobe bronchus with special attention to the peri-
bronchial tissue. Absorbable suture material polydioxanone
(PDS, Ethicon Inc., NJ, USA) was used. A continuous suture to
the membranous wall (PDS, 4/0) and end-to-end anastomosis
with interrupted single stitches (PDS, 3/0) to the cartilagi-
nous part was performed. According to our standard
protocol, patients received induction therapy (anti-thymo-
cyte globulin or basiliximab) and triple immunosuppressive
therapy including cyclosporine, azathioprine or mycopheno-
late mofetil (since 1997) and prednisone. Anti-infective
prophylaxis was used according to our centre’s protocol
described elsewhere [12]. Post-transplant management atour centre includes routine surveillance bronchoscopies with
trans-bronchial biopsies and broncho—alveolar lavage during
the first 6 months after transplant, serial laboratory lung
function tests and regular outpatient clinic follow-up visits.
Donor FEV1 (donor FEV1 (male) = 4.3  height  0.029  -
age; donor FEV1 (female) = 3.95  height  0.025  age)
was calculated and corrected for ppoFEV1 with respect to
size reduction [13]. We estimated ppoFEV1 by using the
following equation: ppoFEV1 = donor FEV1  (1  S
 0.0526), with S = number of resected segments [14]. The
calculated value was correlated with the recipient’s best
FEV1 value measured following transplantation. Donor TLC
(male) = 7.99  height  7.08 and donor TLC (female)
= 6.6  height  5.79 were calculated and corrected for
predicted postoperative TLC (ppoTLC) with respect to size
reduction [13,14].
Pre- and peri-operative variables, outcome and complica-
tions of all patients who underwent size-reduced lung
transplantation were retrospectively analysed and compared
with the patients undergoing standard lung transplantation.
2.1. Statistical analysis
Descriptive statistics was used, and data are expressed as
mean  standard deviation. The statistical analysis was
performed with SPSS 15.0 for Windows. Actuarial survival
rates were calculated by the Kaplan—Meier method and
compared with the log-rank test. To test for univariate
differences in categorical variables, we used Pearson’s chi-
square test. For correlation analysis, Pearson’s correlation
test was used. The Mann—Whitney U-test was used to
compare continuous variables between the groups. p < 0.05
was considered significant.
The University Hospital Zurich’s Research Ethics Commit-
tee granted approval for this study.
3. Results
During the study period, we performed lung transplant
operations in 235 patients. Size-reduced lung transplantation
was performed in 65 patients (27.6%). Three patients who
underwent single-lung transplantation and one heart—lung
transplant patient in the size-reduced group and 25 patients
who underwent single-lung transplantation in the standard
group were excluded. Therefore, 61 recipients in the size-
reduced group and 145 recipients in the standard group were
included in the study. Indications for size-reduced and
standard lung transplantation are displayed in detail in Fig. 1.
In both groups, CF was the most common indication. The
underlying diagnoses were not different between the two
groups ( p = 0.1). Demographic data of both patient groups
are displayed in Table 1.
Size reduction was achieved by lobar transplantation
(n = 20) and anatomic or non-anatomic resections (n = 41).
On the right side, the middle lobe was the most commonly
resected lobe (n = 37), followed by lingula resection (n = 27)
on the left side. Otherwise, downsizing was achieved by right
upper lobectomy (n = 12), right lower lobectomy (n = 1), left
upper lobectomy (n = 14), left lower lobectomy (n = 4) and
non-anatomic wedge resections (n = 19), respectively (more
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Fig. 1. Indications for lung transplantation for recipients who underwent size-
reduced and standard lung transplantation. CF, cystic fibrosis; COPD, chronic
obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; PPH, pri-
mary pulmonary hypertension.
[(Fig._2)TD$FIG]
Fig. 2. Cumulative post-transplant survival according to Kaplan—Meier surviv-
al estimates of the size-reduced (n = 61) and standard groups (n = 145).than one size reductions might have been performed in one
recipient). The mean donor—recipient height difference was
statistically significant between the groups; the mean
donor—recipient weight difference, however, was compar-
able (Table 1). Right ischaemia time in the size-reduced
group was longer than the standard group but comparable for
the left side (Table 1). Total operation time was statistically
longer in the size-reduced group compared with the standard
group (435.9  85.1 vs 385.9  97.4 min, p = 0.0001). Intu-
bation time and intensive care unit stay, however, were
comparable between the two groups.
One patient in the standard group required surgical
revision due to a small bronchial leak on the 5th post-
operative day. Bronchial narrowing without any clinical
implications occurred in two patients in the size-reduced
group and in eight patients in the standard group ( p = 0.09).
The other surgical complications such as prolonged air leak,
pleural effusion and haemorrhage requiring thoracotomy
were comparable between the two groups. The 30-dayTable 1. Patients’ pre-, peri-, and postoperative demographic data.
Size-reduced group Standard group p
N 61 145
Age (years) 40.5  17.7 40.9  14.7 0.9
Female 38 61 0.01
Waiting list time (days) 211.1  217.9 134.01  131.5 0.008
D—R height difference (cm) 11.9  11.5 4.1  7.7 0.0001
D-R weight difference (kg) 16.6  20.1 11.2  18.1 0.08
Ischaemia time; right (min) 257.13  88.9 228.9  81.1 0.03
Ischaemia time; left (min) 323.5  78.4 298.4  85.4 0.09
Total operation time (min) 435.8  85.1 385.9  97.4 0.0001
Intubation time (days) 3.12  5.8 4.36  19.8 0.6
ICU stay (days) 9.75  11.4 10.04  20.8 0.6
Bronchial narrowing (N) 2 8 0.09
Donor ppoFEV1 (l) 2.7  0.6 0.09a
Best FEV1 (l) 2.6  0.7
30-day mortality (%) 4.9 8.3 0.6
5-year survival (%) 74 68 0.4
All values are given as mean  standard deviation. D—R, donor—recipient;
FEV1, forced expiratory volume in 1 s; ICU, intensive care unit; ppoFEV1,
predicted postoperative forced expiratory volume in 1 s.
a Between donor ppoFEV1 and recipient best FEV1.mortality rate was comparable between size reduced and
standard groups (4.9 vs 8.3%), p = 0.6. The 3-month, and 1-
and 5-year survival rates were comparable between the two
groups (90  3%, 86  4% and 74  6% after size-reduced and
89  2%, 85  3% and 68  4% after standard lung transplan-
tation, respectively) (Fig. 2).
In the size-reduced patient group, the mean calculated
and corrected donor ppoFEV1 was comparable with recipi-
ents’ mean best post-transplant FEV1 (2.7  0.6 vs 2.6  0.7
l, p = 0.1). Moreover, the correlation between donor ppoFEV1
and recipient best FEV1 post-transplant was statistically
significant ( p = 0.01, r = 0.688) (Fig. 3). In the size-reduced
patient group, the mean calculated and corrected donor TLC
was comparable with recipients’ mean best post-transplant[(Fig._3)TD$FIG]
Fig. 3. Scatter graph showing the correlation between donor ppoFEV1 and
recipient best FEV1. The correlation was statistically significant (r = 0.688,
p = 0.01). FEV1, forced expiratory volume in 1 s; ppoFEV1, predicted postop-
erative forced expiratory volume in 1 s.
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between donor ppoTLC and recipient best TLC post-
transplant was statistically significant ( p = 0.002, r = 0.617).
4. Discussion
Our study shows that, in size-reduced lung transplanta-
tion, the postoperative recipient best FEV1 could be
predicted from the donor’s calculated and corrected FEV1,
adjusted for the number of transplanted segments. Moreover,
our data demonstrate that size-reduced lung transplantation
can be performed safely with peri- and postoperative
complications and post-transplant outcome is very well
comparable to standard lung transplantation.
Downsizing of lung grafts either by non-anatomical
resection or by lobectomy is one of the methods to increase
the donor pool, especially for small recipients in case of
donor—recipient size mismatch. Nonetheless, it is not
routinely performed in many transplant centres, probably
due to the lack of data on preoperative values to predicting
the functional outcome in size-reduced lung transplant
recipients. In any case, best functional outcome should have
the highest priority when downsizing of lung grafts is
performed. Optimal size matching is also very important
to avoid potential problems, which might occur following the
use of oversized grafts [5—7]. Previous experimental studies
have shown the adverse effects of oversized grafts on chest
mechanics, atelectasis of the graft and pulmonary haemo-
dynamics [15]. In a canine model of bilateral living donor
lobar lung transplantation, both pulmonary vascular resis-
tance and peak airway pressure were significantly increased
after the chest closure due to overcrowding phenomena in
animals that did not undergo size reduction, whereas little
change was observed in those that underwent size reduction
[15]. An oversized graft might lead to perpetual atelectasis or
bronchial distortion with retention of secretions and
increased risk for secondary infection. An oversized graft
might lead to a higher incidence of short-term clinical
complications with reduced improvement in pulmonary
function. Shigemura and co-workers reported the impact
of size reduction for oversized grafts on outcome in
recipients with end-stage restrictive pulmonary disease
[7]. Nine of 25 patients who received oversized grafts
underwent size reduction, whereas 16 recipients did not,
showing better lung function improvement after 6 months in
size-matched recipients, although long-term survival was not
different between groups. The short-term complication rate
was higher in recipients who did receive standard grafts
compared with size-reduced ones [7]. On the other hand,
undersized grafts might lead to persistent pneumothoraces,
hyperexpansion of the lung followed by increased breathing
efforts, and, in extreme cases, even haemodynamic
compromise [5—9]. Optimal size matching is therefore vital.
For optimal size matching, different methods have been
proposed, such as donor—recipient difference or ratio in body
weight and height [5—7]. In addition, chest circumference
and chest X-ray vertical and transverse dimensions have been
used [5]. Others have used donor and recipient TLC [5—8].
Small differences in the lung graft size can be managed by
stapler resection or peripheral non-anatomic wedge resec-tion. In general, the right-side middle lobe and the lingula on
the left side are resected. This technique of size reduction
has been reported to lead to an approximate 10—15%
downsize not only in height but also in anterior—posterior
diameter as the upper lobe rotates towards the lower lobe
[6]. In case of a large size difference, lobar transplantation
should be considered. As previously shown by others, we also
perform donor lung lobectomy on the back table, immedi-
ately before the engraftment. Other than its technical
feasibility of upper lobectomy, the remaining lower lobe
gives a configuration that is similar to the whole lung [6].
Preoperatively, it is important to be able to estimate the
best lung function parameter that can be potentially
achieved in the individual recipient [5]. To avoid functional
impairment, the amount of resected lung tissue has to be
taken into account when size-reduced lung transplantation is
performed [16]. Different opinions exist in the published
literature as to whether postoperative lung function can be
determined by donor or recipient factors [5,17—19]. It has
been shown that postoperative recipient TLC in size-reduced
lung transplantation could be predicted by donor TLC with an
excellent correlation between TLC and FEV1 [5]. In addition,
recipient’s forced vital capacity (FVC) after living lobar lung
transplantation can be predicted by measuring the donor’s
FVC before surgery, regardless of sex, height, weight or
diagnosis of the recipient [15]. These conclusions support our
data that, in size-reduced lung transplantation, donor-
predicted postoperative lung function is important for the
prediction of postoperative recipient lung function. Our data
showed a significant correlation between donor ppoFEV1 and
recipient best FEV1, following size-reduced lung transplanta-
tion. In our study, no significant differences between size-
reduced and standard lung transplant groups were observed
regarding peri- and postoperative complications and survival.
The 30-day mortality was comparable between the groups.
Postoperative intensive care stay and intubation time were
not different; however, the differences in total ischaemic
time, operation time and waiting list time were statistically
significant, in contrast to previous reports [6]. The mean
donor—recipient height difference was also different
between the two groups, supporting the notion that
donor-related parameters are important in predicting post-
operative lung function rather than recipient’s parameters.
Interestingly, a recent US study showed that overall post-
transplant survival or lung function after standard lung
transplantation was unaffected by donor-to-recipient pre-
dicted TLC ratio and actual TLC ratio [20]. The group
concludes that a wider degree of lung size mismatch could be
accepted without adverse effect, which may improve a
patient’s odds of undergoing lung transplantation [20].
In our study, post-transplant survival of the size-reduced
group was 86% at 1 year and 74% at 5 years compared with 85%
1-year and 68% 5-year survival of the standard group,
respectively. All our results are superior compared with ISHLT
Registry overall 1- and 5-year survival rates of 78% and 51%,
respectively, and are comparable to outcome after size-
reduced lung transplantation reported by other centres
[5,6,12].
Our analysis has limitations that are inherent in retro-
spective, single-centre designs. During the 15-year study
period, all transplanted patients were treated with a
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changes occurred regarding induction therapy and the anti-
proliferative agent used, which might have influenced
outcome after transplant.
Thus, we conclude that, in size-reduced lung transplanta-
tion, the postoperative recipient best FEV1 could be
predicted from the donor’s calculated and corrected FEV1
with respect to its size reduction. We believe the methods
used in our study are an additional tool to guiding surgeons
with regard to the optimal reduction of oversized donor
lungs, ensuring that the recipient gets a lung or a pair of lungs
that functions optimally and avoids complications of over-
sizing or undersizing.
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